reason report
lower sale modestli reflect slower growth
bottom line lower revenu
estim
sale estim move
lower estim reflect
conservat around market growth -- particularli within
intermedi risk patient popul -- vs prior expect
project slightli slower tavr market growth vs
previous line consensu still
low-double-digit volum growth suggest tavr survey link
head expect ew deliv tavr sale in-lin
now-low estim y/i q/q
street given tavr survey suggest sequenti
growth forese meaning sale upsid
consensu estim stock nearli ytd
believ ew deliv consist beat rais order
drive upsid share lower sale
estim bring ep estim lower
vs consensu full year ep estim remain
price-to-earnings multipl ep estim pt assum
ew maintain current multipl ep also think
ew market-lead posit highli under-penetrated total
address market justifi compani premium valuat rel
rest large-cap med-tech group
net debt total capit
price-to-earnings lt ep growth
medic suppli devic
ep
compani inform leerink partner llc research
revenu mm non-gaap dilut adjust ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate edward lifesci nyse ew share market perform
price target edward current market leader tavr transcathet aortic
valv replac market intern continu believ tavr
repres one excit new med-tech market high-teen higher
project market compound-annual-growth-rate time-frame base estim sens
ramp less sick patient popul current intermedi risk potenti
low risk beyond might occur slower pace already-elev investor
expect continu believ intermedi risk indic repres massiv
increment market opportun estim intermedi risk doubl
address patient popul also believ ramp patient may slower
saw inoper high risk given linger question around tavr
durabl longer term need seemingli intens market develop effort
drive referr particularli younger less sick portion intermedi risk patient
popul potenti increas surgeon pushback less sick patient popul
heart member ramp effort preserv surgic busi
ultim believ global tavr market exceed line ew
guidanc new indic come on-line low risk eventu asymptomat
near-to-medium term ew still beat rais stori base earli read
intermedi risk adopt ramp think beat next month may
smaller tougher come last two year particularli light
competit launch addit steadier intermedi risk ramp vs step function chang
growth street seem expect share current trade earn
becom increasingli difficult argu meaning multipl expans leav us
upsid current level base estim
price target appli price-to-earnings multipl ep estim
pt assum ew maintain current multipl ep also think ew
market-lead posit highli under-penetrated total address market justifi
compani premium valuat rel rest large-cap med-tech group
risk includ inflect point intermedi risk adopt ramp neg competit
clinic data and/or competit launch delay faster-than-expect low risk
asymptomat trial ramp earlier-than-expect cardiaq feasibl trial re-start
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
incom continu oper
sg sale
 sale
oper expens sale
compani report leerink partner estim
